iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy

Francesca Briganti,Han Sun,Wu Wei,Jingyan Wu,Chenchen Zhu,Martin Liss,Ioannis Karakikes,Shannon Rego,Andrea Cipriano,Michael Snyder,Benjamin Meder,Zhenyu Xu,Gilles Millat,Michael Gotthardt,Mark Mercola,Lars M Steinmetz,Lars M. Steinmetz
DOI: https://doi.org/10.1016/j.celrep.2020.108117
IF: 8.8
2020-09-01
Cell Reports
Abstract:Recent advances in induced pluripotent stem cell (iPSC) technology and directed differentiation of iPSCs into cardiomyocytes (iPSC-CMs) make it possible to model genetic heart disease <em>in vitro</em>. We apply CRISPR/Cas9 genome editing technology to introduce three <em>RBM20</em> mutations in iPSCs and differentiate them into iPSC-CMs to establish an <em>in vitro</em> model of RBM20 mutant <em>dilated cardiomyopathy</em> (DCM). In iPSC-CMs harboring a known causal <em>RBM20</em> variant, the splicing of RBM20 target genes, calcium handling, and contractility are impaired consistent with the disease manifestation in patients. A variant (Pro633Leu) identified by exome sequencing of patient genomes displays the same disease phenotypes, thus establishing this variant as disease causing. We find that all-<em>trans</em> retinoic acid upregulates <em>RBM20</em> expression and reverts the splicing, calcium handling, and contractility defects in iPSC-CMs with different causal <em>RBM20</em> mutations. These results suggest that pharmacological upregulation of RBM20 expression is a promising therapeutic strategy for DCM patients with a heterozygous mutation in <em>RBM20</em>.
cell biology
What problem does this paper attempt to address?